Slides
Page 1
ARR-217 PHASE 1 DATA October 26, 2026
Page 2
1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business plans and objectives for our programs; plans and timelines for the preclinical and clinical development of our product candidates, including the therapeutic potential, clinical benefits and safety profiles of such product candidates; expectations regarding timing, success and data announcements of ongoing and planned preclinical studies and clinical trials, statements regarding our future results of operations or financial condition, business strategy and plans, estimates of the commercial market and revenue potential for our current and future product candidates in current and planned indications, including the potential market opportunity of ARR-217 as monotherapy or in combination; the activity, safety and tolerability of ARR-217 and our other product candidates, as monotherapy or in combination, compared to available therapies; anticipated timing and results of potential milestones, including the timing and results of the global pivotal Phase 3 study of firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR PACC mutations, the timing and results of the Phase 1a and Phase 1b studies of ARR-217, as monotherapy and in combination, in gastrointestinal tumors, the timing and results of the Phase 1 study of ARR-002 and our other ADC candidates; our plans to develop and commercialize our current or future product candidates, the expected benefits of the exclusive license agreement with Allist for ARR-002 in Greater China, and the implementation of our business model and strategic plans for our business, current and any future product candidates. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial condition, expected cash runway, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as ‘‘anticipate,’’ ‘‘assume,’’ ‘‘believe,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘goal,’’ ‘‘intend,’’ ‘‘may,’’ “milestones,” ‘‘objective,’’ ‘‘plan,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘seek,’’ ‘‘should,’’ ‘‘target,’’ ‘‘will,’’ ‘‘would’’ and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, ArriVent’s evaluation of the full data set from its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC as the Company determines the most appropriate development path for firmonertinib, and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 5, 2026, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, filed on May 11, 2026 and August 12, 2026, respectively, and our other filings with the SEC. You should not rely upon forward-looking statements as predictions of future events. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject and are based on information available to us as of the date of this presentation. Although we believe such information forms a reasonable basis for the expectations reflected in the forward-looking statements, such information may be limited or incomplete, and we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to new information, actual results or to changes in our expectations, except as required by law. Unless otherwise indicated, information contained in this presentation concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management’s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that the information from these third-party publications, research, surveys and studies included in this presentation is reliable. Management’s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially from our assumptions and estimates
Page 3
2 A Company Overview Dr. Bing Yao · Co-Founder, Chairman and CEO, ArriVent BioPharma B Our ADC Strategy Dr. Stuart Lutzker · Co-Founder, President R&D, ArriVent BioPharma C ARR-217 Landscape Overview and Initial Phase 1 Data Dr. Priti Patel · Chief Medical Officer, ArriVent BioPharma D Next Steps and Upcoming Milestones Dr. Bing Yao · Co-Founder, Chairman and CEO, ArriVent BioPharma Agenda
Page 4
ArriVent Overview
Page 5
4 Program Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ArriVent Rights Partner Firmonertinib EGFR TKI 1L NSCLC EGFR exon 20 Insertion Mutations Global-Ex China Firmonertinib EGFR TKI 1L NSCLC EGFR PACC Mutations Global-Ex China Firmonertinib EGFR TKI Adjuvant EGFR Uncommon Mutations Global-Ex China ARR-217 CDH17 ADC GI Tumors Global-Ex China ARR-002 NaPi2b x MUC16 ADC Solid Tumors Global Ex-China ARR-421 ADC Solid Tumors Global-Ex China ARR-173 ADC Solid Tumors Global-Ex China Robust Pipeline to Maximize Impact Across Indications & Geographies NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; PACC: P -loop and alpha-c helix compressing; Allist: Shanghai Allist Pharmaceuticals Company, Ltd.; Lepu Biopharma: Lepu Biopharma Co., Ltd.; Alphamab Oncology: Jiangsu Alphamab Biopharmaceuticals, Co., LTD; 1L: First -line therapy; BTD: FDA Breakthrough Therapy Designation. Firmonertinib only approved in China for NSCLC classical EGFR mutations and 2L NSCLC EGFRm exon 20 insertion. ARR-217, ARR-002, ARR-421, and ARR-173 are investigational products and have not been approved by any regulatory authority. Global Ex -China = all countries and regions except mainland China, Hong Kong, Macau and Taiwan. Adjuvant EGFR in uncommon mutations initiated in China. BTD
Page 6
Our ADC Strategy
Page 7
6 Our Antibody Drug Conjugate (ADC) Strategy Creating a pipeline of novel tetravalent, dual-targeting ADCs for targets with overlapping tumor expression Designed to overcome resistance due to heterogenous target expression and target down- regulation More complete tumor targeting decreases the need for companion diagnostic (ex. FOLR1 IHC to identify FRa- high ovarian cancer) Tetravalent for superior activity over bivalent ADCs First or Best-in Class Single-Targeting ADCs Novel Tetravalent, Dual-Targeting ADCs Developing single-targeting ADCs for broadly over- expressed targets Pursuing differentiated molecules with design features for best-in-class potential (i.e., conjugation method, linker, payload) Focusing on areas of high unmet medical need where current standard of care is often chemotherapy DUAL -TARGETINGSINGLE -TARGETING
Page 8
7 TARGET PREVALENCE BY IHC CUTOFF; N CDH17 73% / 98.1% ≥75% IHC3+ / Any staining EpCAM 97.7% IHC3+ data not available / Any staining CEACAM5 71% / 87% ≥75% IHC3+ / Any staining c-MET 35% ≥10% IHC3+ HER2 1–3% ≥10% IHC3+ Cadherin-17 (CDH-17) is Among the Most Highly Over-expressed Targets in Colorectal Cancer Source: Jacobsen F, Pathology Research and Practice, 2024, Went P, British Journal of Cancer, 2006, Decary S, Clinical Cancer Research, 2020, Kopetz S et al., Poster abstract#7056, ESMO 2025, Raghav K, Annals of Oncology, 2026, Enhertu hcp, Arrivent internal TMA data; EpCAM = Epithelial Cell Adhesion Molecule; CEACAM5 = Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; cMET = mesenchymal-epithelial transition factor; HER2= Human epidermal growth factor receptor
Page 9
8 ARR-217 (MRG007) is a Cadherin-17 (CDH17) Targeting ADC Reference: 1. Jacobsen F et al. Pathol Res Pract. 2024 Apr;256:155175. Novel CDH17-Targeting Antibody Drug Conjugate with a Glycan-Linked Exatecan Payload ARR-217 (MRG007) A novel high affinity humanized anti-CDH17 mAb Potent Topo1 inhibitor Exatecan payload (DAR 4) Stable Glycan-based site-specific conjugation Hydrophilic linker to improve PK properties Rapid internalization and enhanced bystander activity in tumor cell lines Robust anti-tumor activity in multiple cell line-derived (CDX) and patient-derived (PDX) xenograft models Well tolerated in monkey studies at highest dose tested (60mg/kg) with minimal GI toxicity conferring a favorable preclinical therapeutic index
Page 10
9 ARR-217 Has Enhanced In Vitro Stability Note: Payload detected by LC-MS/MS Payload LLOQ: 0.1 ng/mL Day 21 0 50 100 150 200 250 0 2 4 6 8 Payload concentration (ng/ml) Percentage of payload release (%) Day 0 Day 1 Day 4 Day 7 Day 14 ADC incubation time Concentration of payload Percentage of payload ARR-217 with glycan-based conjugation (DAR 4) versus ARR- 217 mAb-DXd with inter-chain cysteine conjugation (DAR 8) Improved Stability In Both Human And Non-Human Primate (NHP) Plasma Payload release in human and NHP plasma. ADC conc. 1000 nM ARR-217-human plasma ARR-217 mAb-DXd-human plasma ARR-217-NHP plasma ARR-217 mAb-DXd-NHP plasma
Page 11
10 ARR-217 Has Superior Bystander Activity Target+ vs. Target- cells: 1000 vs. 2000 cells, ADC 1nM, 6 days, detected by operatta Bystander killing on GFP+ SW480-hCDH17 and RFP+ RKO cells Target+ cellsin coculture Target- cellsin coculture Target- cellsonly Medium ARR-217mAb-DXd ARR-217 50 0 100 150 T+cells/untreatedT+cells% orT- cells/untreated T- cells% ✱✱✱ Bystander killing on GFP+ SW480-hCDH17 and RFP+ SW480 WT cells Target+ cellsin coculture Target- cellsin coculture Target- cellsonly100 150 T+cells/untreated T+cells% orT- cells/untreatedT- cells% ✱✱✱✱ 50 0 Medium ARR-217mAb-DXd ARR-217 Schematic of Bystander Effect Int. J.Mol. Sci.2023,24, 13726.
Page 12
11 ARR-217 Has Robust Anti-tumor Activity in Xenograft CRC Models • Activity observed across multiple CDX and PDX CRC models with a range of CDH17 expression levels • Activity comparable or improved over ARR-217 mAb-DXd control despite lower DAR (4 vs 8) CDX Model PDX Model PDX Model
Page 13
ARR-217 (MRG007) Landscape Overview and Initial Phase 1 Data
Page 14
13 5 Colorectal Cancer Remains One of Oncology’s Largest Unmet Needs ~1.9M patients per year, increasing to 3M by 2040 2nd leading cause of cancer death worldwide 13% 5-year survival rate in mCRC Abbreviation: mCRC = metastatic colorectal cancer. Sources: World Health Organization, interactive data; Biller and Schrag, 2021, JAMA; American Cancer Society
Page 15
14 FOLFOX / FOLFIRI ± biologics¹ KRAS/NRAS/BRAF WT (50% of mCRC) Regorafenib • Fruquintinib • Lonsurf • Bevacizumab + Lonsurf FOLFOX / FOLFIRI ± biologics Current Metastatic CRC Treatment Options in the First and Second Line are Biomarker-Driven with Limited Third Line Options 1 Whichever regimen that was not previously given in 1L. 2 If BRAF inhibitor not previously given in 1L. Abbreviations: FOLFIRI = fluorouracil, folinic acid, irinotecan; FOLFOX = fluorouracil, folinic acid, oxaliplatin. mAb = monoclonal antibody; HER2= Human epidermal growth factor receptor. Adapted from Biller and Schrag, 2021. Sources and assumptions: 2035 DRG epidemiology and company estimates regarding pricing assumptions based on approved ADCs; estimated duration of treatment based on mCRC standard of care; SEER Cancer Stat Facts: Colorectal Cancer (Accessed May 2026); Buchler, T. 2022; Kawakami et al., 2015; Jacobsen, L. K., et al. (2024). CDH17 expression by IHC across 14,948 tumors. Poster, AACR 2024; Panarelli, N. C., et al. (2012). American Journal of Clinical Pathology, 138(2), 211–222; Tampellini et al., 2017; McCleary et al., 2022; Bazarbashi et al., 2019; Shinozaki et al., 2021; Koopman et al., 2025 HER2 amplified (2-5% of mCRC) KRAS/NRAS mutant (35-45% of mCRC) BRAF mutant (5-10% of mCRC) MSI-H/MMR-D (5% of mCRC) FOLFOX + EGFR mAb + BRAF inhibitor Immune checkpoint inhibition FOLFOX / FOLFIRI ± biologics EGFR mAb + BRAF inhibitor² FOLFOX / FOLFIRI ± biologics¹ HER2- directed therapy EGFR mAb + G12C KRAS inhibitor LINE OF THERAPY Est. 2035 US incidence 1ST LINE ~90,000 2ND LINE ~67,000 3RD LINE+ ~44,000 1
Page 16
15 Current Standard of Care in 3L+ Metastatic CRC Is Highly Inadequate Current therapies have poor response rates and limited survival benefit 1SUNLIGHT study total patients; Patients previously treated with prior bevacizumab had median PFS of 4.5 months and OS of 9.0 months Abbreviations: ORR = overall response rate; DCR = disease control rate; OS = overall survival; PFS = progression free survival. Sources: Lonsurf® (trifluridine and tipiracil) Fruzaqla® (fruquintinib), Stivarga® (regorafenib) package inserts; Dasari et al. 2023; Grothey et al. 2013; Prager et al. 2023. Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors. 8 Treatment Treatment Line ORR (%) DCR (%) Median PFS (months) Median OS (months) Fruquintinib 3L+ 2% 56% 3.7 7.4 Regorafenib 3L+ 1% 41% 2.0 6.4 Trifluridine / tipiracil 3L+ 2% 44% 2.0 7.1 Trifluridine / tipiracil + Bevacizumab1 3L only 6% 77% 5.6 10.8
Page 17
16 ARR-217 (MRG007) Phase 1 Study Design A multicenter, FIH dose escalation and optimization Phase I Study (NCT07066657) in China and US, evaluates ARR-217 (MRG007) in locally advanced/metastatic solid tumors, including CRC aRandomization previously included dose levels at 7 mg/kg and 8 mg/kg; however, these dose levels were discontinued. CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, objective response rate; RECIST,Response Evaluation Criteria in Solid Tumors. . DOSE OPTIMIZATION/EXPANSIONDOSE ESCALATION BACKFILL Cohort 1: CRC PATIENTS Adults with locally advanced or metastatic solid tumors Failed standard therapy ECOG PS 0 or 1 Measurable disease per RECIST v1.1 PHASE 1A primary objective: Safety 2 mg/kg 4 mg/kg 6 mg/kg 8 mg/kg 4.0 mg/kg 6.0 mg/kg 7.0 mg/kg 8.0 mg/kg Phase 1a PHASE 1B PRIMARY objectives: Safety and primary efficacy endpoint: ORR Phase 1b (ongoing) Ra (1:1) 6 mg/kg 5 mg/kg
Page 18
17 Patient Demographic and Disease Characteristics As of data cutoff (August 5, 2026), 123 patients received ARR-217; 113 had CRC *Unknown primary location in 6 patients (5.3%). ECOG PS, Eastern Cooperative Oncology Group performance status. Characteristic, n (%) or median (range) Overall (N=123) CRC (n=113) Age, years 58.0 (31–79) 58.0 (31–79) Female 41 (33.3) 35 (31.0) Race, n (%) Asian 96 (78.0) 86 (76.1) White 15 (12.2) 15 (13.3) Black/African-American 5 (4.1) 5 (4.4) Other/unknown/not reported 7 (5.7) 7 (6.2) ECOG PS, n (%) 0 27 (22.0) 25 (22.1) 1 96 (78.0) 88 (77.9) Prior lines of systemic therapy 2 (1–9) 3 (1–9) Characteristic, n (%) CRC (n=113) Primary location* Colon, right 29 (25.7) Colon, left 47 (41.6) Rectum 31 (27.4) Liver metastases at baseline 62 (54.9) RAS mutation 66 (58.4) KRAS | NRAS 64 (56.6) | 5 (4.4) BRAF mutation 6 (5.3) Microsatellite stable/proficient mismatch repair 95 (84.1) Prior systemic cancer therapies 113 (100) Irinotecan 95 (84.1) Oxaliplatin 112 (99.1) Anti-VEGF inhibitor 95 (84.1) Anti-EGFR inhibitor 39 (34.5)
Page 19
18 ARR-217 Exhibits Dose Proportional PK with Minimal Payload Exposure Ab, antibody; ADC, antibody-drug conjugate; Cmax, maximum plasma concentration; PK, pharmacokinetic(s); TAb , therapeutic antibody Minimal payload exposure Half-life is 4.6–5.8 days Cmax 2–4 days 2.0 mg/kg 4.0 mg/kg 6.0 mg/kg 7.0 mg/kg 8.0 mg/kg ADC/TAB Similar ADC/TAb PK profiles indicate ADC stability Dose-proportional increase in exposure ADC/TAb half-life is 3.2–4.0 days Payload (Exatecan)
Page 20
19 ARR-217 Has a Manageable Safety Profile Data cutoff: August 5, 2026. AE, adverse event; DLT, dose-limiting toxicity; GI, gastrointestinal; ILD, interstitial lung disease; MTD, maximum tolerated dose; TRAE, treatment-related adverse event; WBC, white blood cell. Characteristic, n (%) or median (range) 2.0 mg/kg (n=3) 4.0 mg/kg (n=6) 5.0 mg/kg (n=18) 6.0 mg/kg (n=49) 7.0 mg/kg (n=25) 8.0 mg/kg (n=22) ALL (N=123) No. of treatment cycles 2 (2–4) 6 (2–15) 1 (1–3) 3 (1–11) 4 (1–8) 6 (1–10) 3 (1–15) Treatment-related AEs Any 3 (100) 5 (83.3) 10 (55.6) 40 (81.6) 24 (96.0) 22 (100) 104 (84.6) Grade ≥3 0 0 0 10 (20.4) 13 (52.0) 14 (63.6) 37 (30.1) Serious 0 0 0 7 (14.3) 8 (32.0) 9 (40.9) 24 (19.5) Leading to Dose interruption 0 1 (16.7) 1 (5.6) 12 (24.5) 7 (28.0) 11 (50.0) 32 (26.0) Dose reduction 0 0 0 2 (4.1) 10 (40.0) 10 (45.5) 22 (17.9) Treatment discontinuation 0 0 0 0 1 (4.0) 0 1 (0.8) Dose intensity (Mean) 99.8% 96.2% 99.9% 94.5% 84.4% 83.6% 91.5% • During dose escalation, MTD was not reached; One patient with DLT (8.0 mg/kg; grade 4 platelet count decrease and grade 4 neutropenia) • Median treatment duration: 85.0 days (range, 21–343) • AEs were most commonly cytopenias & GI toxicities, predominantly grade 1 or 2; no ILD was reported
Page 21
20 ARR-217 Showed Encouraging Preliminary Anti-Tumor Activity Across all doses, 75 treated patients had ≥1 post baseline tumor assessment; median duration of follow-up was 4.17 months (range, 1.2 to 10.6) Data cutoff: August 5, 2026. Subsequent to data cut off, all PRs pending confirmation have subsequently confirmed. CR, complete response; CRC, colorectal cancer; DCR, disease control rate; ORR, objective response rate; PR, partial response; SD, stable disease. PR pending confirmation, patient on treatment but has not received confirmatory scan. Unconfirmed PR, patient off treatment without confirmation Outcomes, % (95% CI) or median (range) 2.0 mg/kg (n=2) 4.0 mg/kg (n=2) 5.0 mg/kg (n=3) 6.0 mg/kg (n=29) 7.0 mg/kg (n=19) 8.0 mg/kg (n=20) ≥4 mg/kg (n=73) ORR (CR + PR) 0 (0, 84.2) 50 (1.3, 98.7) 0 (0, 70.8) 44.8 (26.4, 64.3) 31.6 (12.6, 56.6) 25.0 (8.7, 49.1) 34.2 (23.5, 46.3) DCR (CR + PR + SD) 50.0 (1.3, 98.7) 100 (15.8, 100) 100 (29.2, 100) 93.1 (77.2, 99.2) 89.5 (66.9, 98.7) 90.0 (68.3, 98.8) 91.8 (83.0, 96.9)
Page 22
21 Overall Response Rates Consistent Across Sub-Groups 44.8% 43.5% 50.0% 42.1% 46.7% 42.9% 36.8% 34.7% 0% 20% 40% 60% Overall Prior irinotecan RASwt RASmut 2L and 3L therapy 4L+ therapy US China n = 8 n = 19n = 23 n = 15 n = 14 n = 29 6mg/kg to 8mg/kg n = 19 n = 49 Overall Response Rate
Page 23
22 ARR-217 Phase 1 Data Continues to Mature With Most Patients Continuing on Treatment Data cutoff: August 5, 2026. CRC, colorectal cancer; PR, partial response; SD, stable disease; Tx, treatment. 0 6 12 18 24 30 36 42 48 54 Treatment, weeks 2 mg/kg 4 mg/kg 5 mg/kg 6 mg/kg 7 mg/kg 8 mg/kg PR PD Tx ongoing
Page 24
23 4L+, fourth-line or later; AE, adverse event; DCR, disease control rate; GI, gastrointestinal; ILD, interstitial lung disease; ORR, objective response rate; PK, pharmacokinetics. These results support further clinical development and ongoing Phase 1b dose optimization AEs were primarily low-grade GI and hematologic toxicities (grade ≥3 TRAEs 20.4%; dose reduction 4.1% (2 of 49 patients) 1 patient (of 123; 0.8%) discontinued due to AE Generally well-tolerated safety 44.8% ORR; 93.1% DCR at 6 mg/kg dose for CRC Responses observed regardless of RAS mutation or prior irinotecan treatment, and in 4L+ patients Promising preliminary efficacy ARR-217 Showed Promising Preliminary Antitumor Activity in CRC and a Well-Tolerated Safety Profile
Page 25
Next Steps and Upcoming Milestones
Page 26
25 ARR-217 Has the Potential to be the Best in Class ADC in CRC Based on Initial Efficacy Data ORR 44.8% ORR 34.2% ORR 26.0% ORR 20.0% ORR 31.0% 24.1% 19.2% 19.0% 20.0% 32.0% 20.0% 20.7% 17.5% 24.4% +13.8% +6.8% 0 10 20 30 40 50 ARR-217 6 mg/kg (n=29) ARR-217 4mg/kg and higher (n=73) AMT-676 8 mg/kg (n=47) AMT-676 7.2 mg/kg (n=30) CX-2051 10 mg/kg (n=19) CX-2051 8.6 mg/kg (n=20) M9140 2.8 mg/kg (n=29) Temab-A 2.4 mg/kg (n=40) Temab-A 3.0 mg/kg (n=41) % of evaluable patients ORR incl. unconfirmed (%) cORR at cutoff (%) PR pending confirmation Blank ORR = not reported (CX-2051, Temab-A monotherapy report confirmed ORR only); SUNLIGHT 6.1% is published ORR, confirmation not specified Source: AMT-676 ESMO GI 2026 112P; CytomX CX-2051 release; M9140 ESMO 2025 962P; Temab-A JCO 2026; Data are not from head to head studies. Cross trial data should be considered carefully given differences in study patient population, sample size, inclusion and exclusion criteria among other factors.
Page 27
26 ARR-217 Has the Potential to be the Best in Class ADC in CRC Based on Safety Profile 39.0% 31.0% 85.0% 28.0% 18.0% 2.0% 5.0% 24.0% 0.0% 0.0% 020406080100 Diarrhea All Grade and Grade ≥3 (% of patients) Any-grade diarrhea (%) Grade ≥3 diarrhea (%) 2 13 8 45 40 4 11 3 31 28 4 4 18 8 0 20 40 60 80 100 Grade ≥3 cytopenias (summed %) Anemia Neutropenia Thrombocytopenia ARR-217 6mg/kg CDH17 (n=49) AMT-676 (1.6 – 12mg/kg) CDH17 (n=246) CX-2051 (7.2 – 10mg/kg) EpCAM (n=80) M9140 2.8mg CEACAM5 (n=29) Temab-A 2.4mg c-MET (n=40) Source: AMT-676 ESMO GI 2026 112P; CytomX CX-2051 release; M9140 ESMO 2025 962P; Temab-A JCO 2026;. Data are not from head to head studies. Cross trial data should be considered carefully given differences in study patient population, sample size, inclusion and exclusion criteria among other factors.
Page 28
27 ARR-217 Has the Opportunity to Expand into Earlier Lines of Therapy for CRC and Additional Tumor Types Current Study Phase 1a Phase 1b Phase 3 Phase 1B Monotherapy Ongoing Dose Optimization Study (US and China) Phase 1B Combination with Bevacizumab Ongoing Study (China with US sites planned) Phase 1B Combination with chemotherapy Ongoing Study (China) Potential Phase 1B Additional Tumor Types Planned (US and China) 3L+ CRC 3L+ CRC 2L CRC / 1L CRC 2L+ Pancreatic, Gastric
Page 29
28 Upcoming Planned Milestones PROGRAM PLANNED MILESTONE TIMING Firmonertinib Program update 1Q 2027 ARR-217 Phase 1b dose optimization data 1H 2027 ARR-217 Initial Phase 1b data from combination with bevacizumab 2H 2027 ARR-217 Initial Phase 1b data with chemotherapy YE 2027 ARR-217 Initiation of Phase 3 study YE 2027 ARR-002 Initial Phase 1 data YE 2027